MedTrace Logo

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

NCT05924256 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-04-02

No results posted yet for this study

Summary

This is a single-center, open-label, phase 2 study to evaluate the efficacy and safety of target therapy for patients with relapsed/metastastic salivary gland carcinoma based on molecular typing.

Conditions

  • Advanced Salivary Gland Carcinoma

Interventions

DRUG

SHR-A1811

SHR-A1811

DRUG

SHR 3680 + leuprolide

SHR 3680 + leuprolide

DRUG

SHR-A1921

SHR-A1921

DRUG

SHR-A1811

SHR-A1811

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Dongmei Ji, Doctor · Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-26
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05924256 on ClinicalTrials.gov